Celularity Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Robert Joseph Hariri
- Full Time Employees
- 120
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 170 Park Avenue Florham Park NJ United States of America 07932
- IPO Date
- Aug 8, 2019
- CIK
- 0001752828
- Website
- celularity.com
- Similar Companies
- Business
- Celularity Inc. (Nasdaq: CELU), headquartered in Florham Park, New Jersey, is a clinical-stage biotechnology company leading the next evolution in cellular and regenerative medicine through off-the-shelf, allogeneic, cryopreserved placental-derived cell therapies and advanced biomaterial products targeting cancer, immune disorders, infectious diseases, and degenerative conditions. Founded in 2017 as a spin-out from Anthrogenesis (established 1998), the company utilizes its proprietary IMPACT platform to source, expand, and manufacture cells from postpartum placentas, including unmodified and genetically modified natural killer (NK) cells such as CYNK-001 for relapsed/refractory multiple myeloma and acute myeloid leukemia; CAR T-cells; mesenchymal-like adherent stromal cells (MLASCs); and biomaterial products like BIOVANCE Human Amniotic Membrane Allograft, Tri-Layer BIOVANCE Human Amniotic Membrane Allograft, Interfyl Human Connective Tissue Matrix, and other regenerative tissue allografts for wound care and surgical applications. Celularity operates a fully integrated 150,000 square foot cGMP-capable facility for research, clinical development, manufacturing, and biobanking, generating revenue primarily from its bio-banking segment and biomaterial sales, with geographic focus on the United States and partnerships extending therapeutic reach globally. Recent developments include the October 2024 acquisition of Rebound and related assets from Sequence LifeScience for $5.5 million to expand its wound care portfolio; a strategic partnership and in-kind investment in DefEYE Inc.'s $12 million Series Seed funding round in October 2025, granting DefEYE an exclusive sublicense for ophthalmic applications of Celularity's regenerative biologics; completion of a major balance sheet restructuring retiring $41.6 million in senior secured debt; securing $2.46 million in funding via amended warrant terms in January 2025; and filing of Q1 and Q2 2025 10-Q reports confirming Nasdaq compliance. The company maintains licensing agreements with Sorrento Therapeutics for CD19 CAR-T products and research collaborations with Regeneron Pharmaceuticals for allogeneic cell therapies, positioning it to address unmet needs in scalable, accessible treatments.
Celularity Appoints Rick Gonzalez as Chief Commercial Officer
Celularity Receives Nasdaq Notice Regarding Form 10-Q
Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation
NEXGEL Appoints Ian Blackman as Chief Financial Officer
NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment
Celularity Announces Closing of Transaction with NexGel
Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
KALA BIO (NASDAQ:KALA) vs. Celularity (NASDAQ:CELU) Financial Survey
Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities
EXCLUSIVE: NexGel To Acquire Regenerative Biomaterial Portfolio From Celularity, Expects To Triple Revenue
Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy
Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses
Celularity CEO Comments on Centers for Medicare & Medicaid Services' Withdrawal of Skin Substitute Local Coverage Determinations
Celularity Announces Closing of Financing Transactions
Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision
Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care
Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease
Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) Compliance
Celularity Receives Nasdaq Notice Regarding Form 10-Q
Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt